Doxycycline hyclate (Synonyms: 多西环素盐酸盐半乙醇半水合物; Doxycycline hydrochloride hemiethanolate hemihydrate; WC2031)

目录号: HY-N0565B 纯度: 99.19%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Doxycycline hyclate 是一种具有口服活性的四环素抗生素，是广谱的金属蛋白酶 (MMP) 抑制剂，具有抗菌活性和抗癌细胞增殖活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Doxycycline hyclate Chemical Structure

CAS No. : 24390-14-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
100 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥750	In-stock
10 g	￥1320	In-stock
50 g	￥3850	In-stock
100 g	现货	询价
> 100 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Doxycycline hyclate:

MCE 顾客使用本产品发表的 91 篇科研文献

: Doxycycline hyclate purchased from MCE. Usage Cited in: Cancer Lett. 2016 Jun 28;376(1):188-96. [Abstract]; Doxycycline inducible shRNA can effectivly knockdown the expression of AKT in HCC cells. Cells are treated with 100ng/mL Doxcycline and cultured for the indicated times.

Doxycycline hyclate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

查看 MMP 亚型特异性产品:

查看所有亚型

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
纯度 & 产品资料
参考文献

生物活性

Doxycycline hyclate, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor^[1]. Doxycycline hyclate shows antibacterial activity and anti-cancer cell proliferation activity^[1]^[2]^[3]^[4]^[5].

IC₅₀ & Target

Tetracycline

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34364164]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27654395]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 27155463]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25791675]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 25282267]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24946216]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22889559]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21852132]
HepG2	CC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21741131]
HepG2	IC₅₀	20 μM Compound: doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19926173]
HepG2	IC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19482476]
HT-1080	IC₅₀	21.4 μM Compound: 7	Inhibition of cell invasion in human HT-1080 cells for 24 hrs by Calcein AM staining based fluorometric analysis Inhibition of cell invasion in human HT-1080 cells for 24 hrs by Calcein AM staining based fluorometric analysis	[PMID: 35969157]
K562	IC₅₀	15 μM Compound: doxycycline	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19926173]
K562	IC₅₀	15 μM Compound: Doxycycline	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19482476]
THP-1	IC₅₀	20 μM Compound: Doxycycline	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry	[PMID: 19748781]

体外研究
(In Vitro)

Doxycycline (0.01-10 µg/mL, 4 d) 仅在高浓度下影响胶质瘤细胞的生长^[2]。
Doxycycline (0.01-10 µg/mL, 24 h) 浓度为 1 µg/mL 及更高时降低 SVG 细胞中 MT-CO1 蛋白含量^[2]。
Doxycycline (100 ng/mL, 1 µg/mL; 24 h) 降低人细胞系的增殖^[4]。
Doxycycline (0-250 μM, 72 h) 抑制乳腺癌细胞的活性^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	LNT-229, G55, and U343 glioma cells
Concentration:	0.01, 0.1, 1 or 10 µg/mL
Incubation Time:	4 days
Result:	Affected growth of glioma cells only under high concentrations (10 µg/mL).

Cell Viability Assay^[2]

Cell Line:	SVG cells
Concentration:	0.01, 0.1, 1 or 10 µg/mL
Incubation Time:	24 hours
Result:	Decreaseed MT-CO1 protein content with concentrations of 1 µg/mL and higher.

Cell Proliferation Assay^[4]

Cell Line:	MCF 12A, 293T cells
Concentration:	100 ng/mL, 1 µg/mL
Incubation Time:	96 hours
Result:	Caused reduced proliferation of MCF 12A and 293T cells at 1 µg/mL.

Cell Viability Assay^[5]

Cell Line:	MCF-7, MDA-MB-468 cells
Concentration:	0-250 μM
Incubation Time:	72 hours
Result:	Inhibited breast cancer cells in a dose-dependent manner with IC₅₀ values for MCF-7 and MDA-MB-468 of 11.39 μM and 7.13 μM respectively.

体内研究
(In Vivo)

诱导基因表达的 ON-OFF 体系^[6]^[7]^[8]

致病原理

Doxycycline 在分子生物学研究中常被用作诱导剂，用于诱导基因表达。在构建了 Tetracycline (Tet; HY-A0107) 诱导表达 (Tet-ON/Tet-OFF) 系统的细胞或模型动物中，可以通过添加或去除 Doxycycline 来精确控制目标基因的表达 ON 和 OFF 的状态。Doxycycline 可以在 Tetracycline (Tc) 控制的反式激活 (tTA) 系统中作为转录激活的抑制剂，又在“反向 tTA‘系统中，作为转录激活的诱导剂。Doxycycline 和 Tetracycline 被上消化道吸收后都是在全身起作用。相比之下，Doxycycline 的主要优点是活性更长，并且可以每天服用两次或一次。虽然两者的峰浓度相似，但 Doxycycline 达到峰浓度的时间更短，半衰期明显更长^[6]^[7]^[8]。

具体造模方法

Rat^[8]: male • adult middle-aged (12-month-old) • Sprague-Dawley rats
Administartion (for GDNF regulation): 3g/kg (Doxycycline; HY-N05655) (dietary with regular food) • po once daily for 6 days • monitored every day

Note

1. 该研究^[7]中，使用了重组腺相关病毒 (rAAV) 为基础的双顺反子四环素 (tet)-OFF 构建体，用于对 GDNF (目的基因) 长期表达过程中的动态控制。
2. 3g/kg 膳食 DOX 产生的 DOX 血清水平相当于饮用水中 1mg/ml DOX 的水平。

造模成功指标

（1）目的基因表达水平下降；
（2）与目的基因对应的正相关表型减轻。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-month-old female Heterozygous Col3a1-deficient (HT) mice^[3]
Dosage:	200 or 800 mg/kg
Administration:	Oral gavage; 200 or 800 mg/kg; once daily; 3 months
Result:	Reduced MMP-9 activity in a dose-dependent manner.

Clinical Trial

分子量

512.94

Formula

C₂₃H₂₉ClN₂O₉

CAS 号

24390-14-5

性状

固体

颜色

White to yellow

中文名称

多西环素盐酸盐半乙醇半水合物；强力霉素盐酸盐半乙醇半水合物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 240 mg/mL (467.89 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 125 mg/mL (243.69 mM; 超声助溶)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9495 mL	9.7477 mL	19.4955 mL
5 mM	0.3899 mL	1.9495 mL	3.8991 mL
10 mM	0.1950 mL	0.9748 mL	1.9495 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 3 mg/mL (5.85 mM); 澄清溶液
方案二

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 3 mg/mL (5.85 mM); 澄清溶液

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 20 mg/mL (38.99 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.19%

选择批次：

Data Sheet (662 KB) SDS (393 KB)

COA (300 KB) LCMS (131 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51. [Content Brief]

[2]. Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504. [Content Brief]

[3]. Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7. [Content Brief]

[4]. Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561. [Content Brief]

[5]. Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745. [Content Brief]

[6]. Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67. [Content Brief]

[7]. Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8. [Content Brief]

[8]. Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73. [Content Brief]

Doxycycline hyclate 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.9495 mL	9.7477 mL	19.4955 mL	48.7386 mL
	5 mM	0.3899 mL	1.9495 mL	3.8991 mL	9.7477 mL
	10 mM	0.1950 mL	0.9748 mL	1.9495 mL	4.8739 mL
	15 mM	0.1300 mL	0.6498 mL	1.2997 mL	3.2492 mL
	20 mM	0.0975 mL	0.4874 mL	0.9748 mL	2.4369 mL
	25 mM	0.0780 mL	0.3899 mL	0.7798 mL	1.9495 mL
	30 mM	0.0650 mL	0.3249 mL	0.6498 mL	1.6246 mL
	40 mM	0.0487 mL	0.2437 mL	0.4874 mL	1.2185 mL
	50 mM	0.0390 mL	0.1950 mL	0.3899 mL	0.9748 mL
	60 mM	0.0325 mL	0.1625 mL	0.3249 mL	0.8123 mL
	80 mM	0.0244 mL	0.1218 mL	0.2437 mL	0.6092 mL
	100 mM	0.0195 mL	0.0975 mL	0.1950 mL	0.4874 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Doxycycline hyclate (Synonyms: 多西环素盐酸盐半乙醇半水合物; Doxycycline hydrochloride hemiethanolate hemihydrate; WC2031)

Customer Review

Other Forms of Doxycycline hyclate:

MCE 顾客使用本产品发表的 91 篇科研文献

Doxycycline hyclate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看 MMP 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Doxycycline hyclate 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Doxycycline hyclate (Synonyms: 多西环素盐酸盐半乙醇半水合物; Doxycycline hydrochloride hemiethanolate hemihydrate; WC2031)

Customer Review

Other Forms of Doxycycline hyclate:

Doxycycline hyclate 相关抗体

MCE 顾客使用本产品发表的 91 篇科研文献

Doxycycline hyclate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看 MMP 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Doxycycline hyclate 相关抗体:

摩尔计算器

稀释计算器

Doxycycline hyclate 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z